Polymorphism rs2073618 of the TNFRSF11B (OPG) Gene and Bone Mineral Density in Mexican Women with Rheumatoid Arthritis

Table 2

Comparison of sociodemographic, clinical, and laboratory characteristics between GG genotype carriers and GC or CC genotype carriers in patients with rheumatoid arthritis (RA).

	GG ()	GC or CC ()
Sociodemographic characteristics
Age (yr), mean ± SD	60 ± 9	58 ± 9	0.16
Body mass index (kg/m^2), mean ± SD	28.1 ± 4.4	28.1 ± 4.0	0.95
Disease characteristics
Disease duration (yr), mean ± SD	14 ± 11	13 ± 8	0.70
DAS28 score, mean ± SD	3.5 ± 1.4	3.6 ± 1.6	0.85
HAQ-Di score, mean ± SD	0.49 ± 0.57	0.47 ± 0.52	0.81
Lumbar spine L1–L4 BMD (g/cm^2), mean ± SD	0.97 ± 0.17	1.00 ± 0.19	0.37
Femoral neck BMD (g/cm^2), mean ± SD	0.85 ± 0.17	0.86 ± 0.15	0.55
ESR (mm/hr), mean ± SD	25 ± 11	25 ± 11	0.86
CRP (mg/mL), mean ± SD	15.7 ± 25.9	19.1 ± 32.5	0.56
RF (UI/mL), mean ± SD	170.6 ± 524.8	129.7 ± 229.4	0.68
ACPAs (+), (%)	63/82 (76.8)	26/33 (78.8)	1.00
Anti-CCP2 (RU/mL), mean ± SD	105 ± 131	92 ± 97	0.56
Anti-CCP2 (+), n (%)	48/79 (60.8)	23/33 (69.7)	0.40
Anti-MCV (U/mL), mean ± SD	201 ± 309	345 ± 403	0.04
Anti-MCV (+), n (%)	46/78 (59.0)	20/31 (64.5)	0.67
OPG serum levels (pg/mL), mean ± SD	111.3 ± 71.9	99.7 ± 68.9	0.32
Treatment characteristics
cs-DMARD use, n (%)	98 (80.3)	44 (81.5)	1.00
Monotherapy, n (%)	36 (29.5)	15 (27.8)	0.93
Combinated therapy, n (%)	62 (50.8)	29 (53.7)	0.93
Methotrexate	66 (54.1)	31 (57.4)	0.74
Leflunomide	37 (30.3)	19 (35.2)	0.60
Sulfasalazine	33 (27.0)	14 (25.9)	1.00
Azathioprine	16 (13.1)	11 (20.4)	0.26
Chloroquine	16 (13.1)	9 (16.7)	0.64
Glucocorticoid use, n (%)	85 (69.7)	40 (74.1)	0.59
Glucocorticoid dose (mg), mean ± SD	4.54 ± 5.98	6.54 ± 9.83	0.09

RA: rheumatoid arthritis; BMD: bone mineral density; GG: homozygote genotype; GC: heterozygote genotype; CC: polymorphic homozygote genotype; anti-CCP2: 2nd-generation antibodies against citrullinated proteins; anti-MCV: antimutated citrullinated vimentin antibodies; ACPA: antibodies against cyclic citrullinated peptides/protein including anti-CCP2 (+) or anti-MCV (+); cs-DMARD: conventional synthetic disease-modifying antirheumatic drugs; DAS28: Disease Activity Score for 28 joints; HAQ-DI: Health Assessment Questionnaire-disability index; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; RF: rheumatoid factor. Anti-CCP2 (+) was defined as >5 RU/mL; anti-MCV (+) was defined as >20 RU/mL; combined therapy was defined as the use of two or more cs-DMARDs. Qualitative variables were expressed in frequencies (%) and quantitative variables in means ± standard deviations (SD). Statistical tests: the chi-square test (or the Fisher exact test if applicable) was conducted for comparisons between proportions and independent sample Student t-tests were performed for comparisons between differences in means. values were obtained comparing the GG genotype versus GC or CC genotype.